|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:administered_by
|
gptkb:children
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:average_temperature
|
2 to 8 ° C
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:community_health
|
significant reduction in disease incidence
|
|
gptkbp:contraindication
|
immunocompromised individuals
severe allergic reaction
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:dosage_form
|
0.5 m L
|
|
gptkbp:first_dose_recommended_at
|
12 to 15 months
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
M-M-R II
|
|
gptkbp:introduced_in
|
gptkb:1971
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
88% for mumps
97% for measles
97% for rubella
|
|
gptkbp:is_recommended_by
|
gptkb:CDC
gptkb:WHO
|
|
gptkbp:is_vulnerable_to
|
part of routine immunization programs
long-lasting immunity
efficacy in different populations
impact on public health
recommended by pediatricians
combination vaccine
high in developed countries
low in some developing countries
ongoing studies on safety
routine childhood vaccination
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:second_dose_recommended_at
|
4 to 6 years
|
|
gptkbp:serves
|
gptkb:rubella
gptkb:measles
mumps
|
|
gptkbp:side_effect
|
fever
rash
thrombocytopenia
swelling of glands
febrile seizures
|
|
gptkbp:type
|
live attenuated vaccine
|
|
gptkbp:vaccine_combination
|
gptkb:MMR_vaccine
|
|
gptkbp:bfsParent
|
gptkb:GSK
|
|
gptkbp:bfsLayer
|
4
|